神经母细胞瘤中Topo-Ⅱ表达的临床病理意义及预后分析  

Clinicopathological significance and prognostic analysis of Topo-Ⅱ expression in neuroblastoma

作　　者：李晓晗[1] 王小松[1] 郑华川[2] 马颖[1] 姜卫国[1] 吕庆杰[1] 

机构地区：[1]中国医科大学附属盛京医院病理科,辽宁沈阳110004 [2]中国医科大学,辽宁沈阳110001

出　　处：《现代肿瘤医学》2008年第8期1284-1286,共3页Journal of Modern Oncology

摘　　要：目的:探讨神经母细胞瘤中拓扑异构酶-Ⅱ(Topo-Ⅱ)表达的临床病理及预后意义。方法:采用免疫组化S-P法检测72例神经母细胞瘤组织中Topo-Ⅱ蛋白表达,分析其表达与神经母细胞瘤临床病理特征和患者生存时间的关系。结果:Topo-Ⅱ蛋白在神经母细胞瘤中阳性表达率为45.83%(33/72)。Topo-Ⅱ表达与神经母细胞转移密切相关(P<0.05),而与瘤患者的年龄、性别、肿块大小、肿瘤分化程度、局部浸润和临床病理分期无显著相关性(P>0.05);与患者的生存时间呈负相关(P<0.05)。结论:Topo-Ⅱ蛋白可以作为评价神经母细胞瘤转移和预后的分子生物学指标,研究其表达为神经母细胞瘤的化学治疗和预后评估提供理论依据。Objective：To investigate the expression of Topoisomerase -Ⅱ （Topo -Ⅱ ）and explore its clinicopathological and prognostic significance in neuroblastoma. Methods： Seventy - two cases of neuroblastoma were studied by S - P immunohistochemistry using antibody against Topo -Ⅱ. Its expression was compared with clinicopathological features of neuroblastoma and survival time. Results： The positive rate of Topo-Ⅱ was 45.83% （33/72） in neuro- blastoma. Topo -Ⅱexpression was associated with metastasis of neuroblastoma（ P 〈0.05 ） , without correlation between its expression and age, sex, tumor size, differentiation, clinicopathological staging of neuroblastoma （ P 〉 0.05 ）. Topo -Ⅱ expression positively paralleled with poor outcome of patients with neuroblastoma （ P 〈 0.05 ）. Conclusion： Expression of Topo -Ⅱ protein could be regarded as a molecular biological marker for reflecting metas- tasis and prognosis of neuroblastoma. Studying Topo -Ⅱ expression underlay the theoretic basis to guide chemotherapy and evaluate prognosis in patients with neuroblastoma.

关 键 词：神经母细胞 拓扑异构酶-Ⅱ 预后 

分 类 号：R739.4[医药卫生—肿瘤] R738.6[医药卫生—临床医学]